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Obesity increases human cancer risk and the risk for cancer recurrence. Adipocytes secrete paracrine factors termed adipokines that
stimulate signaling in cancer cells that induce proliferation.The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription
factor that plays roles in tumorigenesis, is regulated by exogenous lipophilic chemicals, and has been explored as a therapeutic
target for cancer therapy. Whether exogenous AHR ligands modulate adipokine stimulated breast cancer cell proliferation has
not been investigated. We provide evidence that adipocytes secrete insulin-like growth factor 2 (IGF-2) at levels that stimulate
the proliferation of human estrogen receptor (ER) positive breast cancer cells. Using highly specific AHR ligands and AHR short
interfering RNA (AHR-siRNA), we show that specific ligand-activated AHR inhibits adipocyte secretome and IGF-2-stimulated
breast cancer cell proliferation. We also report that a highly specific AHR agonist significantly (𝑃 < 0.05) inhibits the expression of
E2F1, CCND1 (known as Cyclin D1), MYB, SRC, JAK2, and JUND in breast cancer cells. Collectively, these data suggest that drugs
that target the AHR may be useful for treating cancer in human obesity.
1. Introduction
Human obesity is common and has been linked with
increases in breast cancer risk and breast cancer recurrence
[1–3]. Although the underlying links between obesity and
cancer are not completely clear, adipocytes themselves are
postulated to play a role [1–9]. Adipocytes secrete multiple
paracrine factors termed adipokines that stimulate signaling
in human cancer cells that stimulate proliferation [4–7, 9].
Specific adipokines that stimulate the proliferation of human
estrogen receptor (ER) positive breast cancer cells are leptin,
collagen VI, and members of the insulin-like growth factor
(IGF) family of proteins [4–6, 8, 9]. In ER positive breast
cancer cells, leptin through its cognate membrane spanning
cytokine leptin receptor activates the JAK/STAT pathway
[6, 10]. Collagen VI by activating the NG2/chondroitin
sulfate proteoglycan receptor activates AKT and 𝛽-catenin
signaling [4, 5]. IGF-1 and IGF-2 signal through specific
cell surface tyrosine kinase receptors, IGF-1 receptor (IGF-
1R) and insulin receptor isoform A (IR-A)), that are highly
expressed on human ER expressing breast cancer cells [11, 12].
The critical pathway by which IGF-1 and IGF-2 stimulate
breast cancer cell proliferation is the PI3K pathway that leads
to increases in AKT activity [11, 12]. Leptin, collagen VI, and
IGF proteins have all been reported to stimulate increases
in the transcription and expression of CCND1 (also known
as Cyclin D1) in ER expressing breast cancer cells [4–6, 12].
CCND1 is a regulatory protein that activates the cell cycle,
increases cell proliferation, and has been implicated as a
promoter of breast tumorigenesis [13]. New drugs and drug
targets that inhibit adipokine stimulated breast cancer cell
proliferation could be particularly relevant to reducing the
higher rates of breast cancer risk and breast cancer recurrence
that are observed in obese women compared to women
of normal weight. However, there are currently no specific
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therapies for reducing breast cancer risk and recurrence in
obesity.
The aryl hydrocarbon receptor (AHR) is a ligand-
activated transcription factor that has been explored as a
therapeutic target for cancer [14, 15]. Ligand-activated AHR
inhibits the growth of some human cancers cell lines [14, 15].
The AHR is stimulated by lipophilic chemicals that func-
tion as AHR agonists including the environmental toxicant
2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) and the experi-
mental drug 3-(3,5-dimethyl-1H-pyrrol-2-yl methylene)-1,3-
dihydro-indol-2-one (SU5416) [14, 16]. In the absence of an
exogenous AHR agonist, the AHR is located in the cytoplasm
bound to p23, HSP90, and XAP2 chaperon proteins [17].
Upon activation by an agonist, the AHR dissociates from
p23, HSP90, and XAP2, translocates into the nucleus, and
stimulates transcription by binding to sequence specific
response elements termed AHR response elements (AHRE)
in enhancers of genes that are stimulated by AHR ligands
[17]. CYP1A1 is a prototypical AHR regulated gene target
that has been used to study AHR signaling [17]. Whether
specific ligand-activated AHR inhibits adipokine stimulated
breast cancer cell proliferation and the potential mechanisms
by which this could occur have not been investigated.
Obese women with ER positive breast tumors have worse
clinical outcomes and have a higher risk for breast cancer
recurrence than obesewomenwith ERnegative breast tumors
[18]. This suggests that ER positive breast cancer cells could
be more sensitive to the proliferative effects of mitogenic
adipokines than ER negative breast cancer cells. The human
ER positive MCF-7 breast cancer cell line has been used
extensively as a model to investigate mitogenic adipokine
signaling in human breast cancer cells and MCF-7 cells,
express leptin, collagen VI, and IGF receptors [4–6, 12].
The human T-47D breast cancer cell line expresses ER and
IGF receptors, and fewer reports have used this cell line to
investigate adipokine signaling in human breast cancer cells
[14]. Given these prior reports, the purpose of this study
was to examine the possibility that specific ligand-activated
AHR inhibits mitogenic adipokine signaling in humanMCF-
7 breast cancer cells and to provide preliminary insights into
the mechanism by which this occurs. Primary findings were
also validated in T-47D cells.
2. Material and Methods
2.1. Conditioned Media. A previously published standard
adipocyte differentiation protocol was used to differentiate
murine 3T3-L1 preadipocyte fibroblasts into fully differen-
tiated adipocytes [4]. Specifically, confluent 3T3-L1 fibrob-
lasts were treated with Dulbecco’s Modified Eagle Medium
(DMEM), 10% FBS, 160 nM insulin, 250 nM dexamethasone,
and 0.5mM 3-isobutyl-1-methylxanthine (IBMX)) for 3 days,
followed by 10% fetal bovine serum (FBS) and 160 nM insulin
for 3 days and then DMEM 10% FBS for an additional 6
days, with a medium change every three days. In order to
examine the effects of adipocyte secreted adipokines in the
absence of confounding factors in FBS,mediumwas removed
from fully differentiated adipocytes, followed by rinsing twice
with phosphate buffered saline (PBS), and adipocytes were
then incubated in phenol red-free, serum-free DMEM for
an additional 24 hr. This serum-free adipocyte conditioned
medium (adipo-CM) was centrifuged and stored at −80∘C
prior to being applied to breast cancer cells in cell culture.
Phenol red-free, serum-free DMEM conditioned by 3T3-L1
fibroblasts for 24 hrs was also isolated. Fibroblast conditioned
medium (fibro-CM) was applied to breast cancer cells as
a control media not conditioned by an adipocyte. DMEM,
FBS, P/S, and PBS were purchased from Thermo Fisher
Scientific (HyClone Labs, Logan, UT). IBMX, insulin, and
dexamethasone were purchased from Sigma-Aldrich (St.
Louis, MO).
2.2. Breast Cancer Cell Growth Experiments. Prior to spe-
cific growth experiments, MCF-7 and T-47D cells (ATCC,
(Manassas, VA)weremaintained inDMEM, 10% FBS, and 1%
penicillin/streptomycin (P/S). To explore whether adipo-CM
stimulated cancer proliferation more than fibro-CM, phenol
red-free, serum-freeDMEM(unconditionedmedium), fibro-
CM, or adipo-CM was applied to MCF-7 or T-47D cells for
three days in culture, after which cells were collected and
total live cell numberwas determined using a hemocytometer
and manual cell counting. Preliminary experiments were
conducted to determine the optimal dose of TCDD to use in
proliferation experiments. In our preliminary experiments,
we found that MCF-7 cells were more sensitive to the
antiproliferative effects of TCDD than, T-47D cells (data not
shown 𝑛 = 3). Thus, in all remaining experiments, MCF-7
cells were treated with 10 nM TCDD and T-47D cells were
treated with 100 nM TCDD. The 100 nM dose of SU5416 was
selected based on our preliminary data showing that SU5416
at this dose is a strong AHR agonist based on its ability
to stimulate increases in CYP1A1 gene expression (data not
shown; 𝑛 = 3). Fibro-CM or adipo-CM supplemented with
DMSO vehicle, TCDD, or SU5416 was applied to overnight
serum-starved (phenol red-free DMEM) MCF-7 or T-47D
cells for three days in culture, after which cells were collected
and trypan blue and manual cell counting were used to
determine live cell number. In other experiments, overnight
serum-starved (phenol red-free DMEM) MCF-7 or T-47D
cells were stimulated with PBS vehicle or IGF-2 (100 ng/mL;
R & D Systems) supplemented with DMSO vehicle, TCDD,
or SU5416 for three days in culture, after which cells were
collected and live cell was determined with trypan blue. The
IGF-2 dose was based on the work of Worster et al. showing
that IGF-1 (100 ng/mL) induced the proliferation of human
breast epithelial cells [19].
2.3. SiRNA Experiments. In order to show that TCDD and
SU5416 inhibition of IGF-2 requires the AHR, breast cancer
cells were plated in DMEM, 10% FBS, and P/S (80,000
cells per well of a 6-well plate) for 24 hr, then transiently
transfected with 50 nM of a single short interfering RNA
(siRNA) that specifically targets the AHR (AHR-siRNA)
or with a nontargeting control siRNA (con-siRNA) with
2 𝜇L of DharmaFECT reagent 1 for 24 hr. Following removal
of transient transfection reagent, cells were serum-starved
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overnight in phenol red-free DMEM and then treated with
IGF-2 (100 ng/mL) supplemented with DMSO vehicle or
TCDD (MCF-7 (10 nM), T-47D (100 nM)) or SU5416 (MCF-
7 100 nM) for three days in culture, after which cells were
collected and trypan blue was used to determine the num-
ber of live cells. Con-siRNA (cat number D-001810-01-20),
AHR-siRNA (J-004990-05), and DharmaFECT transfection
reagent number 1 were purchased from Thermo Scien-
tific, Dharmacon. DMSO and SU5416 were purchased from
Sigma-Aldrich (St. Louis, MO). TCDD was purchased from
Cambridge Isotopes Laboratory (Andover, MA) (cat number
ED-901-B).
2.4. Western Blot Experiments. To validate AHR-siRNA
mediated knockdown of the AHR, breast cancer cells
(300,000 cells per 35mm plate) were transfected with con-
siRNA or AHR-siRNA for 36 hr, followed by isolation of
total cellular extract in 250 𝜇L of 2X sample lysis buffer (Bio-
RAD; cat number 161-0737). Total cellular extract (∼12.5 𝜇g
of protein) was subjected to SDS PAGE in Mini-PROTEAN
TGX 4–12% Precast Gels (Bio-Rad; Hercules, CA) and trans-
ferred to polyvinylidene difluoride (PVDF)membranes (Bio-
Rad; Hercules, CA). Membranes were blocked in PBS, 0.05%
Tween 20 (PBS-T), and 5% (wt/vol) low-fat powdered milk
for 1 hr, followed by overnight incubation at 4∘Cwith rocking
with an appropriate primary antibody. Membranes were
rinsed five times (five minutes each wash) with PBS-T and
then incubated with an appropriate HRP-labeled secondary
antibody (Thermo Scientific, Pierce) for 1 h, followed by
rinsing five times (five minutes each wash) in PBS-T followed
by the application of enhanced chemiluminescent substrate
(Thermo Scientific, Millipore) and exposure to X-ray film
(Midwest Scientific). Equal protein loading was confirmed
by glyceraldehyde 3-phosphate dehydrogenase (abbreviated
as GAPDH) western blots. AHR antibody was purchased
from Santa Cruz Biotechnology, cat number: sc-5579, and
diluted 1 : 5,000 in PBS, 0.01% tween-20, and 5% powdered
milk. GAPDHwas purchased fromMillipore, cat #:MAB374,
and diluted 1 : 20,000 dilution in PBS, .01% tween-20, and 5%
powdered milk.
2.5. RT-qPCR Experiments. A RT2 Profiler PCR Array
(PAHS-502ZC) (Superarray Bioscience Corporation, Qia-
gen) was used to compare gene expression between MCF-
7 cells treated with IGF-2 (100 ng/mL) plus DMSO vehicle
and MCF-7 cells treated with IGF-2 (100 ng/mL) plus TCDD
(10 nM) for 48 hrs. The PAHS-502ZC PCR array allows
for the integration of 84 genes that are prooncogenes or
tumor suppressors and thus are key genes in tumorigenesis.
Treatments were stopped, total RNA was isolated (RNeasy
Mini Kit, Qiagen), and 1 𝜇g of RNA was converted into
cDNA (RT2 First Strand Kit, Qiagen). cDNA was combined
with RT2 SYBER Green ROX qPCR Master Mix (Qiagen),
and changes in gene expression were analyzed by RT2
Profiler PCR Array (PAHS-502ZC). Statistically significantly
differentially expressed genes between groupswere calculated
by RT2 Profiler PCR Array Data Analysis software package
that calculates ΔΔ CT calculated fold changes and uses
Student’s t-test to calculate two-tail, equal variance 𝑃 values.
Experiments were performed 3 times (𝑛 = 3).
2.6. IGF-2 Blocking Antibody Experiments. In order to
explore whether adipocytes secreted levels of IGF-2 are
sufficient to stimulate the proliferation of breast cancer cells,
a control mouse IgG (5𝜇g/mL) (R & D systems, cat number
MAB002) or human IGF-2 blocking antibody (5 𝜇g/mL) (R
& D Systems, cat number MAB292) was added to adipo-
CM prior to being added to human breast cancer cells for
three days in culture, after which total live cell number
was determined using trypan blue. This particular IGF-II
blocking antibody was selected because it has been shown to
specifically neutralize human IGF-2 in MCF-7 proliferation
assays and exhibits 100% cross-reactivity with mouse IGF-2
(R & D Systems product sheet, cat number MAB292).
2.7. Mouse Adipokine Array Kit. Protein adipokine arrays
were purchased from R&D systems (Minneapolis, MN, cat
number ARY-013) and conducted in accordance with the
manufactured protocols. Normalized adipokine levels were
calculated as the density of a specific adipokine divided by
the density of an internal loading control on each array.
Densitometry was calculated with ImageJ PC-based software
(National Institute of Health).
2.8. Statistical Analysis. All experiments were performed for
a minimum of three times. One way analysis of variance
(ANOVA), followed by Student-Newman-Keuls Post-Hoc
Tests, was performed to determine statistically significant
differences betweenmultiple groups. Student’s t-test was used
to determine statistically significant differences between two
groups. All statistical tests were run at a 95% confidence
interval, and significance was denoted as 𝑃 < 0.05.
3. Results and Discussion
3.1. Adipocytes Secrete IGF-2 at Levels That Stimulate Breast
Cancer Cell Proliferation. The application of adipocyte con-
ditioned medium (adipo-CM) to MCF-7 or T-47D breast
cancer cells for three days in culture significantly (𝑃 < 0.0001
and 𝑃 < 0.005, resp.) increased proliferation more than the
application of fibroblast conditioned medium (fibro-CM) or
unconditioned medium (uncond-M) (Figures 1(a) and 1(b)).
Adipokine protein arrays revealed that the levels of several
adipokines in adipo-CM were significantly higher than in
fibro-CM, including insulin-like growth factor-2 (IGF-2) (by
approximately 3-fold; (𝑃 < 0.05)) (Figures 1(c) and 1(d)).
Since the levels of IGF-2 were higher in adipo-CM than in
fibro-CM (Figures 1(c) and 1(d)), andMCF-7 and T-47D cells
overly express IGF-1R and IR-A [11, 12], we questioned the
role of IGF-2 in adipo-CM. The addition of a specific IGF-2
blocking antibody to adipo-CM significantly reducedMCF-7
(𝑃 < 0.0003) andT-47D (𝑃 < 0.05) proliferation compared to
control cells incubated in adipo-CM containing a nonspecific
control IgG (Figures 1(e) and 1(f)). This result suggests that
adipocyte secreted IGF-2 contributes to the proliferation of
ER expressing breast cancer cells.
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Figure 1: Continued.
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Figure 1: Adipocytes secrete levels of IGF-2 that contribute to adipo-CM stimulated breast cancer cell proliferation. (a, b) The total number
of live MCF-7 (a) and T-47D (b) cells grown in unconditioned (uncond-M), fibroblast (fibro-CM), or adipocyte (adipo-CM) conditioned
medium for three days in culture was determined and is shown relative to the number of live cells in the uncond-M group, which was
arbitrarily assigned a value of 1. Data shown are the means ± S.E. for three replicate experiments, and significant (𝑃 < 0.05) induction of
cell number by fibro-CM (∗) compared to the uncond-M group or by adipo-CM (∗∗) compared to the uncond-M and fibro-CM groups is
shown. (c, d) Adipokine protein arrays were used to determine the relative levels of adipokines in adipo-CM and fibro-CM. (d) Data shown
are the means ± SE for three experiments, and significantly (𝑃 < 0.05) higher levels of an adipokine in adipo-CM (∗) compared to fibro-CM
are shown. Normalized adipokine levels were calculated as the densitometry of an adipokine normalized to the densitometry of an internal
loading control. (e, f) The total number of live MCF-7 (e) and T-47D (f) cells treated with nonspecific IgG (5 𝜇g/mL) or a specific IGF-2
blocking antibody (5 𝜇g/mL) in adipo-CM for three days in culture was determined and is displayed relative to the number of live cells in the
fibro-CM nonspecific IgG group, which was arbitrarily assigned a value of 1. Data shown are the means ± S.E. for three replicate experiments.
A significant (𝑃 < 0.05) decrease in cell number by IGF-2 antibody (∗) is shown.
3.2. Ligand-Activated AHR Inhibits Adipo-CM and IGF2
Stimulated Breast Cancer Cell Proliferation. TCDD is a highly
specific AHR agonist [17]. The application of adipo-CM plus
TCDD to MCF-7 and T-47D cells significantly (𝑃 < 0.0001
and 𝑃 < 0.002, resp.) reduced proliferation compared to
that observed in control cells stimulated with adipo-CM
in the presence of vehicle DMSO (Figures 2(a) and 2(b)).
Conversely, MCF-7 and T-47D proliferation in fibro-CMwas
not inhibited by TCDD (Figures 2(a) and 2(b)). These data
suggest that activation of the AHRwith a highly specific AHR
ligand specifically inhibits themitogenic effects of adipokines
that are present in the adipo-CM.
Next, we conducted experiments to determine whether
TCDD inhibits IGF-2 stimulated breast cancer cell pro-
liferation. Treating MCF-7 and T-47D cells with IGF-2
(100 ng/mL) plus TCDD significantly (𝑃 < 0.0001 and
𝑃 < 0.0034, resp.) inhibited proliferation compared to that
observed in control cells stimulated with IGF-2 plus DMSO
vehicle (Figures 2(c) and 2(d)). This result indicates that
activation of theAHRby a highly specificAHRagonist blocks
IGF-2 stimulated breast cancer cell proliferation.
To provide further evidence that ligand-activated AHR
inhibits the proliferation effects of adipokines, we tested a
second AHR agonist, SU5416 [16]. The application of adipo-
CM with SU5416 significantly (𝑃 < 0.0001) inhibited MCF-
7 cell proliferation compared to that observed in adipo-
CM plus DMSO vehicle group (Figure 2(e)). SU5416 did
not reduce breast cancer cell number in the presence of
fibro-CM (Figure 2(e)). Further, SU5416 significantly (𝑃 <
0.001) blocked IGF-2 stimulated MCF-7 cell proliferation
(Figure 2(f)). Collectively, these data indicate that exogenous
AHR ligands inhibit the proliferative effects of mitogenic
adipokines (including IGF-2) in human ER expressing breast
cancer cells.
3.3. AHR Ligand-Stimulated Inhibition of IGF-2 Requires
the AHR. Next, experiments were conducted to provide
evidence that exogenousAHR ligands inhibit the proliferative
effects of adipokines through a mechanism that is depen-
dent on the AHR. To this end, MCF-7 and T-47D cells
were transiently transfected with a short interfering RNA
that specifically targets the AHR (AHR-siRNA) or with a
nontargeting control siRNA (con-siRNA) prior to treatment
with IGF-2 (100 ng/mL) supplementedwithDMSOvehicle or
TCDD.The level of AHR protein in AHR-siRNA transfected
MCF-7 and T-47D cells was significantly (𝑃 < 0.0002 and
𝑃 < 0.0001, resp.) lower than in con-siRNA transfected
cells (Figures 3(a) and 3(b)). In the presence of con-siRNA,
TCDD significantly (𝑃 < 0.001) inhibited IGF-2 stimulated
MCF-7 proliferation (Figure 3(b)). Reducing the AHR in
the presence of IGF-2 significantly (𝑃 < 0.001) inhibited
proliferation relative to control cells treated with con-siRNA
plus IGF-2 (Figure 3(b)). This result suggests that in the
absence of exogenous AHR ligands, the AHR itself plays an
endogenous role in MCF-7 cells that is required for maximal
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Figure 2: AHR ligands inhibit adipo-CM and IGF-2 stimulated breast cancer cell growth. (a, b) The total number of live MCF-7 (a) and
T-47D (b) cells treated with DMSO vehicle or TCDD in fibro-CM or adipo-CM for three days in culture was determined and is displayed
relative to the number of live cells in the fibro-CM DMSO control group, which was arbitrarily assigned a value of 1. Data shown are the
means ± S.E. for three experiments, and a significant (𝑃 < 0.05) decrease in cell number by TCDD (∗) is indicated. (c, d) The total number
of MCF-7 (c) and T47D (d) cells treated with DMSO or TCDD alone or plus IGF-2 (100 ng/mL) for three days in culture was determined
and is displayed relative to the number of live cells in the DMSO group, which was assigned a value of 1. Data shown are the means ± S.E.
for three experiments, and a significant (𝑃 < 0.05) decrease in cell number by TCDD (∗) is indicated. (e, f) The total number of MCF-7 cells
stimulated with DMSO or SU5416 in fibro-CM or adipo-CM (e) or with DMSO or SU5416 alone or plus IGF-2 (100 ng/mL) for three days in
culture was determined and is displayed relative to the number of live cells in the DMSO group, which was assigned a value of 1. Data shown
are the means ± S.E. for three experiments, and a significant (𝑃 < 0.05) decrease in cell number by TCDD (∗) is indicated.
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Figure 3: AHR ligand-stimulated inhibition of IGF-2 requires the AHR. (a, c) MCF-7 (a) or T-47D (c) cells transiently transfected with
con-siRNA or AHR-siRNA for 36 hr, followed by isolation of total cellular extract and western blot analysis with AHR and GAPDH antibody.
GAPDH was used to normalize between samples. Data shown are the means ± S.E. of three experiments. A significant (𝑃 < 0.05) decrease
in AHR by AHR-siRNA (∗) is indicated. (b, d)The total number of MCF-7 (b) or T-47D (d) cells transfected with nontargeting control short
interfering RNA (con-siRNA) or aryl hydrocarbon receptor siRNA (AHR-siRNA) for 36 hr and then treated with DMSO, vehicle control
(con), IGF2 (100 ng/mL) plusDMSOor IGF2 plus TCDD (MCF-7; 10 nM, T-47D; 100 nM) for three additional days in culture was determined
and is displayed relative to the number of live cells in the DMSO con-siRNA group, which was assigned a value of 1. Data shown are the
means ± S.E. of three experiments. (e) The total number of MCF-7 cells transfected with con-siRNA or AHR-siRNA for 36 hr and then
treated with DMSO vehicle control (con), IGF2 (100 ng/mL) plus DMSO, or IGF2 plus SU5416 (100 nM) for three additional days in culture
was determined and is displayed relative to the number of live cells in the DMSO con-siRNA group, which was assigned a value of 1. Data
shown are the means ± S.E. of three experiments.
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Table 1: Gene expression profiling shows significantly (𝑃 < 0.05) reduced expression of proto-oncogenes in MCF-7 cells stimulated with
IGF-2 plus TCDD compared to cells stimulated with IGF-2 at 48 hrs after treatment (𝑛 = 3).
Symbol Description P value Fold regulation
E2F1 E2F transcription factor 1 0.042684 −4.0169
CCND1 Cyclin D1 0.007724 −3.1767
MYB V-myb myeloblastosis viral oncogene homolog (avian) 0.026054 −3.1760
SRC V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 0.027237 −2.5269
JAK2 Janus kinase 2 0.028474 −2.0015
JUND Jun D proto-oncogene 0.026855 −2.0066
proliferation in the presence of IGF-2. Importantly, as shown
in Figure 3(b), reducing AHR prevented TCDD inhibition
of IGF-2 (Figure 3(b); compare last two right bars). This
latter result provides evidence that TCDD inhibits IGF-2 by
activating the AHR, because TCDD does not inhibit IGF-2
in cells with reduced expression of the AHR (Figure 3(b)).
The TCDD-stimulated inhibition of IGF-2 by AHR was
further confirmed in T-47D cells, which showed the TCDD
antiproliferative effects towards IGF-2 were reversed upon
AHR knockdown (Figures 3(c) and 3(d)).
To provide evidence that a different AHR ligand also
inhibits IGF-2 by specifically activating the AHR, AHR-
siRNA experiments were repeated with SU5416. As shown
in Figure 3(e), under con-siRNA conditions, SU5416 signif-
icantly (𝑃 < 0.0001) inhibited IGF-2 stimulated MCF-7 cell
proliferation. In accordance with our prior result, reducing
the AHR itself inhibited MCF-7 cell proliferation in the
presence of IGF-2 compared to control cells transfected with
con-siRNA and stimulated with IGF-2 (Figure 3(e)). AHR-
siRNA blocked SU5416 inhibition of IGF-2 (Figure 3(e);
compare last two right bars). Collectively, these data provide
mechanistic evidence that upon activation by exogenous
AHR agonists TCDD and SU5416, the AHR inhibits IGF-2
stimulated MCF-7 and T-47D proliferation.
3.4. TCDDStimulates Reductions in E2F1, CCND1,MYB, SRC,
JAK2, and JUND Gene Expression. To begin to investigate
the mechanism by which ligand-activated AHR inhibits
proliferation, experiments were conducted to determine
whether TCDD reduces the expression of genes that could be
important for breast cancer cell proliferation in the presence
of IGF-2. To this end, we used a commercially available
RT2 Profiler PCR Array that is capable of integrating 84
genes that are prooncogenes or tumor suppressors and thus
key regulators of tumorigenesis. We focused on comparison
between two groups, MCF-7 cells stimulated with IGF-2 and
MCF-7 cells cotreated with IGF-2 plus TCDD for 48 hrs.This
analysis revealed that the expression of E2F1, CCND1, MYB,
SRC, JAK2, and JUND was significantly reduced in cells
treated with IGF-2 plus TCDD compared to that observed in
cells stimulated with IGF-2 (Table 1; 𝑛 = 3). TCDD inhibition
of these specific gene targets could be one mechanism by
which ligand-activated AHR inhibits mitogenic adipokine
signaling, because the observed downregulated genes in
TCDD treated cells play important roles in breast cancer
cell proliferation. E2F1 is a transcription factor that binds
retinoblastoma protein, enhances the proliferation of human
cancer cells, and stimulates increases in the transcription and
expression of CCND1 [20]. The tyrosine kinase JAK2 upon
activation by cytokine receptor induced signaling to stimulate
the phosphorylation and activation of STAT3 [10]. When
activated by JAK2, STAT3 promotes the transcription and
expression of CCND1 [6]. The basic leucine zipper (bZIP)
transcription factor JUNDby function as a component of AP-
1 enhances the transcription and expression of CCND1 [21].
MYP is 17 beta-estradiol regulated transcription factor that
has been reported to be important for the proliferation of ER
expressing human breast cancer cells, including T-47D and
MCF-7 cells [21].
4. Conclusion
In summary, we provide evidence that adipocyte secreted
IGF-2 is sufficient to contribute to the proliferation of human
ER expressing breast cancer cells. This result suggests that
adipocyte secretion of IGF-2 could play a role in promoting
breast cancer in the context of obesity. Adipocytes have
also been reported to secrete IGF-1 in the presence of high
glucose and exogenously added fatty acids [8]. Both IGF-
1 and IGF-2 enhance the proliferation of human cancer
cells through IGF-1R and IR-A [11, 12]. Using highly specific
AHR agonists and AHR-siRNA, we provide the first evidence
suggesting that specific ligand activation of the AHR inhibits
adipo-CM and IGF-2-stimulated proliferation of ER positive
human breast cancer cells. It is important to note that E2F1,
SCR, JAK2, and JUND are critical upstream transcriptional
regulators of CCND1 [6, 10, 20, 22]. Thus, their downreg-
ulation by TCDD (Table 1) could be one mechanism by
which TCDD downregulates CCND1 expression. CCND1 is
also a critical mediator of the proliferative effects of IGF
proteins and other adipokines like leptin [6, 12]. Therefore,
TCDD inhibition of CCND1 expression (Table 1) is likely
to be one of the major mechanisms that inhibit mitogenic
adipokine signaling in breast cancer cells. The results of this
study provide the impetus for future study investigating the
transcriptional mechanisms by which ligand-activated AHR
by regulating the expression of prooncogenes modulates
mitogenic adipokine signaling in human breast cancer cells.
Collectively, this report provides evidence that drugs that
target the AHR may reduce breast cancer risk in the context
of human obesity.
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